admin – page 6 – eisai china lnc.-威尼斯人888

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into an industry-academia-government joint research agreement with four universities in japan concerning the “industrialization of japan-originated toll-like receptor research by academia-industry collaborating all-japan system: creation of new drug for sle treatment”, which is a research project with eisai as the representative research organization. this joint research project was selected by the japan agency for medical research and development (amed) for its cyclic innovation for clinical empowerment (cicle) grant program. in this project, eisai aims at creating a japan-originated therapeutic drug for systemic lupus erythematosus (sle) through industry-academia-government collaboration, using its in-house discovered new oral toll-like receptor (tlr) 7/8 inhibitor e6742.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that eisai korea inc., eisai’s subsidiary in south korea, has received marketing approval of parkinson’s disease treatment equfina® (safinamide mesilate, “safinamide”) for the indication of treatment of idiopathic parkinson’s disease as adjunctive therapy with levodopa-containing products in patients with end of dose motor fluctuations from the regulatory authority in south korea (ministry of food and drug safety).

abbvie gk (headquarters: minato-ku, tokyo; president: james feliciano, hereafter “abbvie”) and eisai co., ltd. (headquarters: tokyo; ceo: haruo naito, hereafter “eisai”) today announced an approval of partial changes in the marketing approval of humira® (generic name: adalimumab [recombinant], hereafter “humira”), a fully human anti- tnfα monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (q2w) regimen as a treatment option for patients with hidradenitis suppurativa (hereafter “hs”) after the first 4 weeks of treatment.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito) announced today that it has been selected as “most honored company” and has been ranked first place overall in the biotechnology & pharmaceuticals sector of “the all-japan executive team”, released by the us financial information magazine “institutional investor”. this selection is based on eisai’s being ranked first place in “best ceos” and “best cfos”, respectively, in the sector.

the 6th gastrointestinal & liver disease treatment forum (hereinafter referred to as “give”), which was hosted by eisai china inc. and consisted of two sessions, completed successfully on mar. 20 and mar. 27 separately. in order to avoid people gathering during the epidemic outbreak, the forum was held online innovatively.